SARS-CoV-2 Neutralization Antibody eCLIA is intended for in vitro quantitative determination of neutralizing antibodies to SARS-CoV-2 in human serum and plasma. The SARS-CoV-2 Neutralization Antibody eCLIA as an aid in indentifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection.
